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There is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that
tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to
vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological
patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose
COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the
control group (n= 102). Forty-four out of 59 immune cell types were significantly altered in patients; those with monoclonal
gammopathies showed greater immunosuppression than patients with B-cell disorders and Hodgkin lymphoma. Immune
dysregulation emerged before treatment, peaked while on-therapy, and did not return to normalcy after stopping treatment. We
identified an immunotype that was significantly associated with poor antibody response and uncovered that the frequency of
neutrophils, classical monocytes, CD4, and CD8 effector memory CD127low T cells, as well as naive CD21+ and IgM+D+ memory
B cells, were independently associated with immunogenicity. Thus, we provide novel immune biomarkers to predict COVID-19
vaccine effectiveness in hematological patients, which are complementary to treatment-related factors and may help tailoring
possible vaccine boosters.
Blood Cancer Journal          (2021) 11:202 ; https://doi.org/10.1038/s41408-021-00594-1
INTRODUCTION
The novel coronavirus disease 2019 (COVID-19) pandemic has
spread throughout the world, with over 249 million confirmed
cases globally and more than 5 million deaths as of November
2021 (https://covid19.who.int/). Compared with the general
population, cancer patients are at greater risk of serious COVID-
19-related complications and fatal outcome [1, 2]. Higher
mortality was observed in hematological patients when compared
to those with solid tumors [3–6], which likely reflects immune
impairment from the underlying blood cancer as well as therapies
that disable innate, B, and T-cell immunity [5, 7–10]. According to
large studies, nearly one-third of individuals with hematological
malignancies have died with COVID-19 [11–13]. Thus, effective
vaccination against severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2) is of utmost importance to prevent COVID-19
in these patients.
There was great concern that individuals with cancer may not
mount a robust protective immune response to SARS-CoV-2
vaccination and initial reports investigating vaccine effectiveness
in this population showed that antibody production was more
likely to occur in patients with solid tumors than in those with
hematological malignancies [14–16]. Subsequent studies across
the spectrum of hematological malignancies uncovered remark-
able heterogeneity in response to vaccination, with the poorest
rates of seropositivity being generally observed in patients with
B-cell chronic lymphocytic leukemia (CLL), non-Hodgkin lym-
phoma, and multiple myeloma (MM) [17]. By contrast, seroconver-
sion was higher in cases with acute leukemia, chronic myeloid
leukemia, myelodysplastic syndromes, and Hodgkin lymphoma
[18, 19]. After these initial observations, larger and disease-specific
studies in patients with B-cell and plasma cell (PC) disorders were
most recently reported.
The efficacy of SARS-CoV-2 vaccine in CLL patients was 39.5%
and 75% in two large Israeli and UK studies [20, 21]. In both
cohorts, increased rates of seronegativity were associated with
immunoparesis and the use of Bruton’s tyrosine kinase inhibitors.
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By contrast, the negative impact of venetoclax and anti-CD20
therapy was not consistent. In patients with B-cell lymphoma,
seronegativity was found to be associated with indolent vs.
aggressive subtypes and with B-cell suppressive therapies
[18, 22, 23]. Nonetheless, poor serological responses were
observed in some patients who did not receive therapy in the
past 2 years [18]. In MM, clinically relevant antibody responses
were generally observed in ≥50% of patients [18, 24–30]. Although
suboptimal seroconversion was common on active treatment,
discordant results on the impact of anti-CD38 and anti-BCMA
antibodies, as well as steroids were reported [26–28, 30].
The great heterogeneity observed in the efficacy of vaccines
for COVID-19 among hematological patients is probably asso-
ciated with both therapy-related immunosuppression and
disease-related immune dysregulation. Thus, we conducted a
prospective study to determine the immune landscape of
patients with a mature B-cell and PC neoplasm prior vaccination
and its relationship with antibody response after two doses of
SARS-CoV-2 vaccine. We hypothesized that immune profiling
prior vaccination could be complementary to other clinical




A total of 83 patients with hematological malignancies and 102 health care
practitioners (HCPs), vaccinated between January and June 2021, were
studied (Fig. 1A). Only HCP older than 50 were included as the control
group to match the expected age of patients. All subjects had no
documented SARS-CoV-2 infection. Peripheral blood and serum were
collected prior to the first dose, at days 7 and 14 after the first dose, at day
7 after the second-dose and at day 100 after the first-dose vaccination. The
study was approved by the Ethics Committee of the Comunidad Foral de
Navarra (2021.006) and was conducted per the ethical principles of the
Declaration of Helsinki. All HCP and patients provided written informed
consent prior enrollment in the study. Samples and data from subjects
included in the study were provided by the Biobank of the University of
Navarra and were processed following standard operating procedures
approved by the Ethical and Scientific Committees. No data were collected
regarding vaccination side effects or toxicities, as this was outside the
scope of the study.
Assessment of serological response
Antibody response at day 7 after second-dose vaccination and at day 100
after first-dose vaccination (in 100 HCP and 79 patients) was assessed
using a CE-IVD serological SARS-CoV-2 multiplex bead-based flow
cytometry immunoassay (Immunostep SL, Salamanca, Spain) (Fig. 1B)
[31]. It allows the simultaneous and quantitative detection of specific IgM,
IgG, and IgA antibodies to four different viral antigens present in serum:
(1) the receptor-binding domain (RBD) of the S-glycoprotein; (2) the
stable trimer of the spicule (S) glycoprotein; (3) the nucleocapsid (N)
protein; and (4) the main virus protease (Mpro). Detection of antibodies
against the N and Mpro antigens allows the identification of individuals
infected with SARS-CoV-2 before or during vaccination. Thus, the assay
enabled the accurate discrimination between vaccinated and naturally
infected individuals (i.e., negative and positive for both antigens,
respectively).
First, samples were diluted (1 : 20 and 1 : 200 to respectively measure
IgM/IgA and IgG antibodies in HCP; 1 : 10 and 1 : 100 to respectively
measure IgM/IgA and IgG antibodies in patients) before incubation with
beads, at which stage there is binding of antigen-specific antibodies to
the respective proteins that are coating the beads. Each bead has a
unique fluorescence intensity pattern and is coated with one of the SARS-
CoV-2 antigens enumerated above (RBD, S, N, and Mpro). After washing
to remove unbound antibodies, fluorophore-conjugated anti-human IgM
(PE-Cy7), IgG (fluorescein isothiocyanate, FITC), and IgA (PE) were added
to quantify antigen-specific antibodies bound to beads. After another
washing step, beads were suspended and the fluorescence intensity was
measured in the PE-Cy7, FITC, and PE channels, which is proportional to
the amount of IgM, IgG, and IgA antibodies present in serum,
respectively. Samples were analyzed in a CytoFlex LX (Beckman Coulter
[BC] Life Sciences, IN) using the CytExpert v2.3 software (BC) and in an
Aurora (Cytek Biosciences, CA) using the SpectroFlo v3.0.0 software
(Cytek). Antibody indexes were calculated following the manufacturer’s
formula [(mean fluorescence intensity of the sample/mean fluorescence
intensity of the negative control provided in the kit) × 10] and detection
of antibodies was considered positive if antibody indexes were ≥12. The
assay is calibrated following the WHO First International Standard for
Anti-SARS-CoV-2 Human Immunoglobulin (NIBSC Code 20/136). Thus, we
reported the concentration of IgG in international units (IU/mL) against
RBD or in binding antibody units (BAU/mL) against S viral antigens. The
dilution range to obtain a lineal regression model (r ≥ 0.99) was of 1 : 8 to
1 : 16,384.
Immune profiling
Peripheral blood was collected in EDTA containing tubes and processed
within 24 h following the EuroFlow lyse-wash-and-stain protocol (adjusted
to 106 nucleated cells) [32]. Eight-color monoclonal antibody combinations
(Supplemental Table 1) were developed to enumerate major lymphocyte
and myeloid compartments (Fig. 1C) and characterize the relative
distribution of granulocytes, antigen-presenting cells (APCs), T-cell, and
B-cell subsets within each of these compartments (Fig. 1C–E). Overall, 59
immune cell types were systematically evaluated in peripheral blood of
hematological patients and HCP (Supplemental Fig. 1 and Supplemental
Table 2). Samples were measured in a FACSLyric flow cytometer (Beckton
Dickinson Biosciences [BD], San Jose, CA, USA) using FACSuite
v1.3.0.6137 software (BD).
Computational flow cytometry analysis
Data were analyzed using FlowCT, a semi-automated workflow developed
for deconvolution of immunophenotypic data and objective reporting on
large datasets [33]. Briefly, FlowCT starts by creating a matrix with
expression data generating a SingleCellExperiment object and correcting
possible discrepancies in markers’ nomenclature. Subsequently, it performs
internal data quality control and normalization, and automated clustering
followed by dimensionality reduction to visualize clusters’ identity before
manual annotation. This step is completed using the Infinicyt software
(Infinicyt v2.0; Cytognos SL, Salamanca, Spain). Afterwards, sub-clustering
of APC, T, and B cells was performed. Comma-separated value files with
population abundances were finally exported to evaluate statistical
correlations and differences across groups.
Statistical analysis
Immune profiles and seroconversion were compared between HCP vs.
patients, and between groups of patients using proportions of immune
cell types and antibody indexes or concentrations. The Kruskal–Wallis and
Mann–Whitney tests were performed to estimate the statistical signifi-
cance observed between groups and the χ2 and Mann–Whitney U-tests
were performed to test distributions between immunotypes resulting
from unsupervised clustering. Logistic regression was performed to
analyze the relationship between clinical and immune covariates in
predicting antibody response to SARS-CoV-2 vaccination (defined as
≥553.5 IU/mL anti-RBD IgG) in hematological patients. First, cutoffs were
calculated for the 59 immune cell types to maximize the area under the
receiver operating characteristics curve (AUC). χ2 and odds ratio univariate
analyses were subsequently performed to filter variables associated with
antibody response (P < 0.1). Further feature selection for immune
covariates was performed using lasso regularization for logistic regression
(scikit-learn), where coefficients of nonsignificant or multi-colinear
variables are shrunk to 0. A logistic regression machine learning model
was generated for six immune and two clinical covariates and evaluated
using fourfold cross-validation.
All statistical analyses were performed using the GraphPad Prism
(version 7, San Diego, CA, USA), SPSS (version 25.0.0, IBM, Chicago, IL, USA),
and R (version 4.0.0) software. Machine learning analyses were performed
using Python (version 3.8.6) and scikit-learn (version 0.23.2). P-values of
<0.05 were considered statistically significant.
RESULTS
Characteristics of hematological patients and HCP
The median age of patients and HCP was 55 (Table 1). There was
an increased proportion of female HCP, whereas other variables
such as body mass index > 30 and comorbidities such diabetes,
L.-E. Tamariz-Amador et al.
2
Blood Cancer Journal          (2021) 11:202 
hypertension, and autoimmune disease were generally balanced
between patients and HCP. All but one patient and seven HCP
received mRNA SARS-CoV-2 vaccines; 59% of patients were
administered BNT162b2, whereas 66% of HCP were vaccinated
with mRNA-1273 (Table 1).
Of the 83 patients enrolled, seven had Hodgkin lymphoma
and the remaining 76 had a mature B-cell or PC neoplasm
(Table 2). There were seven cases diagnosed with CLL, 25 with
indolent and 16 with aggressive non-Hodgkin lymphoma
subtypes and 28 patients had a monoclonal gammopathy
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(one monoclonal gammopathy of undetermined significance,
two smoldering and 25 active MM). The median time from
diagnosis was 3 years (range, 0.2–26). Although the scope of the
study was in patients with a mature B-cell or PC neoplasm,
those with Hodgkin lymphoma were not excluded from the
study population due to less information on the vaccine
effectiveness in this disease. In addition, it allowed the
comparison of immune profiles in patients with Hodgkin
lymphoma vs. patients with a B-cell lymphoproliferative
disorder or a monoclonal gammopathy.
At the time of vaccination, 17 (20.5%) patients had never
received anti-tumor treatment, 17 (20.5%) were on-therapy,
and 49 (59%) were off. The median number (and range) of lines
in patients on and off-treatment was 2 (1–4) and 1 (1–5),
respectively. Among treated patients, 54/66 (82%) were in
complete response (CR) and 12/66 (18%) in less than CR
(Table 2).
Immune landscape of hematological patients and HCP
When compared to HCP, 44 of the 59 (75%) immune cell types
evaluated in peripheral blood were significantly altered in
patients belonging to at least one of the three main disease
categories: B-cell lymphoproliferative disorders (28/59, 47%),
monoclonal gammopathies (43/59, 73%), and Hodgkin lym-
phoma (12/59, 20%). The B-cell compartment was similarly
skewed in patients with a B-cell and a PC neoplasm vs. HCP.
Those with monoclonal gammopathies showed additional
redistribution of CD4 and CD8 T-cell subsets, as well as of
APC (Fig. 2 and Supplemental Fig. 2). All three regulatory T
(Treg) cell types identified in this study were significantly
reduced in cases with a B-cell and PC neoplasm; two follicular
Fig. 1 Study design. A Peripheral blood and serum from 83 patients with hematological malignancies and 102 health care practitioners (HCP)
were analyzed. B Antibody response at day 7 after the second-dose vaccination was measured using a CE-IVD serological SARS-CoV-2
multiplex bead-based flow cytometry immunoassay. It allows the simultaneous and quantitative detection of specific IgM, IgG, and IgA
antibodies to four different antigens present in serum: (1) the receptor-binding domain (RBD) of the S-glycoprotein; (2) the stable trimer of the
spicule (S) glycoprotein; (3) the nucleocapsid (N) protein; and (4) the main virus protease (Mpro). Detection of antibodies against the N and
Mpro antigens allows the identification of individuals infected with SARS-CoV-2 prior or during vaccination. C Immune profiling of
hematological patients and HCP prior vaccination was performed using multidimensional and computational flow cytometry. A total of 59
immune cell types were systematically measured in peripheral blood, including basophils, eosinophils, neutrophils, antigen-presenting cells
(APC) and lymphocytes. D APC were sub-clustered into classical, intermediate, SLAN− and SLAN+ non-classical monocytes, as well as
plasmacytoid and myeloid dendritic cells (pDC and mDC, respectively). E Sub-clustering of T cells into 32 subsets related to antigen-
dependent differentiation, as well as activation and exhaustion phenotypes in helper and cytotoxic compartments. F Sub-clustering of B cells
into 18 subsets related to antigen-dependent differentiation. CM, central memory; EM, effector memory; TEMRA, effector memory T cells
re-expressing CD45RA; Tfh, follicular helper T cells; Treg, regulatory T cells; CPCs, circulating plasma cells.
Table 1. Characteristics and type of vaccine for COVID-19






Age, median (range), years 55 (50–69) 55 (21–85)
Male, no. (%) 10 (10%) 45 (54%)
Comorbidities, no. (%)
Any 25 (24.5%) 21 (25%)
Body mass index > 30 11 (11%) 13 (16%)
Diabetes 0 (0%) 7 (8%)
Hypertension 8 (8%) 11 (13%)
Autoimmune disease 7 (7%) 3 (4%)
Hematological malignancy, no. (%)
B-cell lymphoproliferative disorders - 48 (58%)
Monoclonal gammopathies - 28 (34%)
Hodgkin lymphoma - 7 (8%)
Type of vaccine, no. (%)
BNT162b2 28 (27.4%) 49 (59.0%)
mRNA-1273 67 (65.7%) 33 (39.8%)
ChAdOx1 7 (6.9%) 1 (1.2%)
Table 2. Seroconversion in 83 patients with hematological
malignancies.
Disease Patients
B-cell lymphoproliferative disorders 36/48
Chronic lymphocytic leukemia 4/7
Indolent non-Hodgkin lymphoma 18/25
Follicular lymphoma 10/14




Aggressive non-Hodgkin lymphoma 14/16
Diffuse large B-cell lymphoma 9/10
Cutaneous B-cell lymphoma 2/3
Burkitt lymphoma 2/2
Mediastinal B-cell lymphoma 1/1
Monoclonal gammopathies 17/28
MGUS 1/1
Smoldering multiple myeloma 2/2













Autologous stem cell transplantation 14/20
Depth of response before vaccination in treated patients
Complete response 54/66
No complete response 12/66
L.-E. Tamariz-Amador et al.
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helper (Tfh) cell types were additionally skewed in those with
monoclonal gammopathies. Patients with Hodgkin lymphoma
displayed mild deregulation of the B- and T-cell compartments,
and the most significant alterations were observed in APC.
Interestingly, a significant increment of classical and inter-
mediate monocytes was found across hematological patients.
Tumor-related immune dysregulation and therapy-related
immunosuppression
Next, we analyzed the immune status of HCP compared to that of
patients that had never received anticancer therapy (i.e., tumor-
related immune dysregulation), were on-treatment or had
finalized their regimen (i.e., therapy-related immunosuppression).
Fig. 2 The immune landscape of hematological patients and HCP. A Supervised clustering of 83 patients with hematological malignancies
and 102 health care practitioners (HCP), based on the percentile distribution of 59 immune cell types in peripheral blood that were
categorized into five groups: granulocytes, antigen-presenting cells (APC), CD4, and CD8 T cells and B cells. Patients were grouped based on
the diagnosis of a B-cell lymphoproliferative disorder (B-cell dis.), monoclonal gammopathies (MG), and Hodgkin lymphoma (HL). B Statistical
significance of differences across groups (with graphical representation of such differences in Supplemental Fig. 2). CM, central memory; EM,
effector memory; Treg, T regulatory cells; Tfh, T follicular-like; TEMRA, terminally effector memory CD45RA+; PC, plasma cells. *P < 0.05;
**P < 0.01; ***P < 0.001; n.s., not significant.
L.-E. Tamariz-Amador et al.
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When comparing the relative distribution of the 59 immune cell
types to that of HCP, patients that were on and off-treatment
showed more frequent alterations than those that were never
treated (39/59 [66%], 33/59 [56%], and 20/59 [34%], respectively).
An increased frequency of classical and intermediate monocytes
was, once more, found across hematological patients, whereas
other granulocytic cell types and APC were less altered (Fig. 3 and
Supplemental Fig. 3). The antigen-dependent differentiation of
CD4 and CD8 T cells was frequently altered in patients on and off-
treatment, whereas it was similar between HCP and patients that
were never treated. The most significant differences within the
T-cell compartment were observed in CD4 and CD8 naive and
central memory subsets, as well as in Treg and Tfh cell types.
Alterations found in 13 out of the 18 B-cell subsets analyzed in this
study were observed in patients that were never treated, peaked
to 18/18 in those on active therapy, and did not bounce back once
treatment finalized (15/18).
Antibody response in hematological patients and HCP
Based on the antibody index of IgG against the RBD antigen
(which is the major target for virus-neutralizing antibodies [34]),
the percentage of patients that tested positive at day 7 after the
second-dose vaccination was significantly inferior than that of HCP
(59/83 [71%] vs. 98/102 [96%], respectively; P < 0.001). Further-
more, the antibody indexes of IgG and IgA against the RBD
antigen were significantly lower in patients vs. HCP (Fig. 4A).
Similar results were observed for anti-S antibody response
(Supplemental Fig. 4).
Seropositivity was more frequent in patients with Hodgkin
lymphoma (6/7, 86%) and B-cell lymphoproliferative disorders (36/
48, 75%) when compared to those with monoclonal gammopa-
thies (17/28, 61%) (Table 2). Seroconversion rates were greater in
patients who never received treatment (14/17, 82%), dropped
considerably in those on-therapy (6/17, 35%), and bounced back
once patients were off-treatment (39/49, 80%). Furthermore,
antibody detection was more frequent in patients who received
one (35/44, 80%) vs. two or more lines of therapy (10/22, 45%).
Previous treatment with anti-CD38 monoclonal antibodies reduced
to half the chances of immunogenicity (6/12, 50%), particularly in
patients that were on active treatment. The negative impact of
autologous transplant (14/20, 70%) and anti-CD20 therapy (22/27,
81%) in seroconversion rates was less pronounced. Patients in
complete remission (40/54, 70%) were more frequently seroposi-
tive than those in other response categories (19/29, 66%).
Further analyses of antibody titers according to international
units showed that hematological patients had significantly
reduced anti-RBD IgG (median 553 vs. 6014 IU/mL; P < 0.001)
and anti-S IgG (median 912 vs. 5313 BAU/mL; P < 0.001) compared
to HCP. Median anti-RBD IgG levels were of 1262, 279, and
2634 IU/mL in patients with B-cell lymphoproliferative disorders,
monoclonal gammopathies, and Hodgkin lymphoma, respectively.
Thus, patients with a PC disorder had significantly lower anti-RBD
IgG titers when compared to the other two disease categories
(Fig. 4B). Median anti-RBD IgG levels were systematically higher in
HCP vs. patients, regardless of whether the latter had never been
treated or if they were on or off-therapy (3871, 133, and 719 IU/
mL, respectively). Notwithstanding, the concentration of anti-RBD
IgG was significantly lower in patients on active treatment vs.
those that were off (P= 0.001) or had never received anti-tumor
therapy (P < 0.001) (Fig. 4C). Similar results were observed for anti-
S IgG titers (data not shown). Patients vaccinated with mRNA-1273
displayed significantly higher anti-RBD IgG levels than those
vaccinated with BNT162b2 (1535.64 vs. 412.88 IU/mL, respectively;
P= 0.016). No differences were observed in HCP (Supplemental
Fig. 5). As expected, anti-RBD IgG titers significantly decreased
from day 7 after second-dose to day 100 after first-dose
vaccination in patients (553–249 IU/mL, P < 0.001) and HCP
(6014–355 IU/mL, P < 0.001).
Undocumented SARS-CoV-2 infection in hematological
patients and HCP
Seventeen of the 102 (17%) HCP and 13/83 (16%) patients tested
positive for the N and Mpro virus-specific antigens, and therefore
were unaware of being infected with SARS-CoV-2 before or during
vaccination. As expected, anti-RBD IgG titers were significantly
higher in HCP previously exposed to SARS-CoV-2 when compared
to those who were not (median 14,104 vs. 4817 IU/mL,
respectively), and a similar kinetics was observed in patients
(median 3368 vs. 458 IU/mL, respectively). Interestingly, the fold-
change in anti-RBD IgG levels between previously infected and
non-infected patients was higher than that observed in HCP
(seven- vs. threefold, respectively), without statistically significant
differences in the median concentration of anti-RBD IgG after two
doses of SARS-CoV-2 vaccine between previously infected patients
and non-infected HCP (Fig. 4D). There were no statistical
differences in the distribution of the 59 immune cell types in
HCP with or without previous infection, and the same applied for
the comparison between patients.
Immunotypes associated with poor antibody response
After observing altered immune profiles prior to vaccination, and
lower seroconversion rates and reduced antibody production after
vaccine administration in patients vs. HCP, we next aimed to
perform a holistic analysis of patients’ demographics and disease
features, treatment, and immune landscape, in relation to
seroconversion and the generation of relevant concentrations of
anti-RBD IgG antibodies. To this end, we stratified patients
according to titer levels: lower or >553.5 IU/mL. This cutoff was
selected because it represented the median concentration of anti-
RBD IgG found in the 83 hematological patients and because it
segregated most HCP (95/102 [93%]) from a few with clearly lower
titers (Supplemental Fig. 6). Vaccine effectiveness in reducing the
incidence of symptomatic and asymptomatic SARS-CoV-2 infec-
tion was reported to be >90% in HCP [35–37]. In fact, in our cohort
only 4/102 (4%) developed (mild) COVID-19 after vaccination.
Thus, it can be inferred that the presence of ≥553.5 IU/mL anti-
RBD IgG confers protection to COVID-19.
The first two branches after unsupervised clustering analysis
according to the relative distribution of the 59 immune cell types,
divided the 83 hematological patients in 2 groups: 1 with 55 (66%)
and another, smaller and more homogeneous with 28 (34%)
patients (Fig. 5). When compared to the larger branch, the smallest
was characterized by lower seroconversion rates (8/28 [29%] vs.
45/55 [82%], P= 0.006) and <553.5 IU/mL anti-RBD IgG (7/28
[25%] vs. 35/45 [78%], P= 0.002). Half of the patients in the
smallest branch had a B-cell lymphoproliferative disorder and the
other half, a monoclonal gammopathy; by contrast, all cases with
Hodgkin lymphoma clustered in the larger branch (P= 0.03).
Patients belonging to the smaller branch were older (P= 0.007)
and had received treatment more frequently (P= 0.002) including
≥2 lines of therapy (P= 0.018). Treatment with anti-CD38
antibodies (P= 0.02) and immunomodulatory drugs ([IMiDs],
P= 0.0099) was more frequent in these patients as well. Gender,
exposure to anti-CD20 or autologous transplant, the type of
vaccine, and previous SARS-CoV-2 infection were not significantly
associated with patients’ branch.
The two branches were characterized by altered distribution of
granulocytes, APC, CD4 and CD8 T cells, as well as B cells (Fig. 5
and Supplemental Fig. 7). Neutrophils and classical monocytes
were significantly increased in patients belonging to the smaller
branch, whereas SLAN+ non-classical monocytes were reduced.
Within the T-cell compartment, the frequency of 17/19
CD4 subsets and of 8/13 CD8 subsets were significantly decreased
in patients belonging to the smaller branch. All 18 subsets of the
B-cell compartment were markedly reduced in these cases.
Overall, this holistic analysis uncovered the presence of a distinct
immunotype that was significantly associated with weak
L.-E. Tamariz-Amador et al.
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Fig. 3 Tumor-related immune dysregulation and therapy-related immunosuppression. A Relative distribution of granulocytes, antigen-
presenting cells (APC), CD4 and CD8 T cells, and B cells across health care practitioners (HCPs), hematological patients that had never received
treatment (No tx, N= 17), those that were on (Active tx, N= 17), and patients that were off-treatment (Post-tx, N= 49) before vaccination.
B Statistical significance of differences across groups (with graphical representation of such differences in Supplemental Fig. 3). APC, antigen-
presenting cells; CM, central memory; EM, effector memory; Treg, T regulatory cells; Tfh, T follicular-like; TEMRA, terminally effector memory
CD45RA+; PC, plasma cells. *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not significant.
L.-E. Tamariz-Amador et al.
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Fig. 4 Antibody response in hematological patients and HCP. A Index of IgM, IgG, and IgA antibodies against the receptor-binding domain
(RBD) of the S-glycoprotein in health care practitioners (HCP, N= 102) and hematological patients (N= 83). B Concentration of anti-RBD IgG in
HCP, hematological patients with B-cell lymphoproliferative disorders (B-cell dis., N= 48), monoclonal gammopathies (MG, N= 28) and Hodgkin
lymphoma (HL, N= 7). C Concentration of anti-RBD IgG in HCP, hematological patients that had never received treatment (No Tx, N= 17), those
that were on (N= 17), and patients that were off-treatment (N= 49) before vaccination. D Concentration of anti-RBD IgG in HCP and
hematological patients with or without previous SARS-CoV-2 infection, based on the detection of IgG antibodies against the nucleocapsid (N)
protein and the main virus protease (Mpro). Among HCP, 85 were negative and 17 positive for both antigens. Among hematological patients, 70
were negative and 13 positive for both antigens. In all panels, horizontal lines represent the median. *P < 0.05; **P < 0.01; ***P < 0.001.
L.-E. Tamariz-Amador et al.
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immunogenicity, as well as patients’ age, disease category,
treatment status, and previous exposure to anti-CD38 antibodies
and IMiDs. As these two agents were frequently administered in
the same patients, either simultaneously or in different lines, the
isolated effect of each drug cannot be determined.
Immune biomarkers of immunogenicity
Optimal cutoffs for association with the generation of relevant
concentrations of anti-RBD IgG antibodies were determined for
percentages of each of the 59 immune cell types based on their
AUC (Supplemental Table 3). Using these cutoffs, the frequencies
of 43 immune cell types were significantly associated with less or
>553.5 IU/mL anti-RBD IgG. Lasso regression was subsequently
performed for feature selection, and six immune cell types were
selected by the algorithm for logistic regression multivariate
analysis: neutrophils, classical monocytes, CD4 and CD8 effector
memory CD127low T cells, as well as naive CD21+ and IgM+D+
memory B cells. Clinical parameters significantly associated with <
or >553.5 IU/mL anti-RBD IgG were the diagnosis of a monoclonal
gammopathy (P= 0.03), treatment status (P < 0.001), number of
prior lines of therapy (P= 0.003), and anti-CD38 therapy (P= 0.03).
Diagnosis of a monoclonal gammopathy decreased the model’s
accuracy and was therefore excluded from the logistic regression.
Other patient-related or disease-related characteristics, including
age and treatment with IMiDs, were not significantly associated.
On logistic regression multivariate analysis, the six immune cell
types and two clinical parameters showed independent predictive
value (Fig. 6A). Whereas no prior therapy and increased
frequencies of both B-cell subsets were associated with
>553.5 IU/mL anti-RBD IgG, prior exposure to anti-CD38 therapy,
and the expansion of neutrophils, classical monocytes, and the
two T-cell subsets, were associated with lower antibody titers (Fig.
6A, B). The AUC of the logistic regression model was 0.90 (Fig. 6C),
with only partial correlation between immune and clinical
covariates (Fig. 6D). Any attempt to simplify the model by
removing one or more of the parameters described above,
significantly impaired its accuracy (data not shown). Cross-
validation scores for four folds of the data generated AUC of
0.89, 0.80, 0.88, and 0.95, suggesting that the model may yield
accurate predictions to new unseen data (Fig. 6E). Thus, these
Fig. 5 Immunotypes associated with poor antibody response. Unsupervised clustering of 83 hematological patients and 102 health care
practitioners (HCPs) based on the relative percentile distribution of 59 immune cell types in peripheral blood before vaccination, categorized
into four groups: granulocytes, antigen-presenting cell (APC) subsets, T-cell and B-cell subsets. For the columns to the left of the cell-
percentage data, moving from left to right, rows are color-coded according to gender, age groups, type and subtype of hematological
malignancy, treatment status, number of previous lines of therapy, immunoparesis, autologous transplant, treatment with anti-CD20
antibodies, anti-CD38 antibodies and immunomodulatory drugs (IMiDs), depth of response to treatment (complete remission, CR), previous
SARS-CoV-2 infection, and vaccine type. For the columns to the right of the cell-percentage data, moving from left to right, rows are color-
coded according to seroconversion and presence of ≥553.5 IU/mL IgG against the receptor-binding domain (RBD) of the S-glycoprotein.
CM, central memory; EM, effector memory; Treg, T regulatory cells; Tfh, T follicular-like; TEMRA, terminally effector memory CD45RA+;
PC, plasma cells.
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results identify six immune biomarkers predictive of weak
immunogenicity, which are independent of patient’ demographics
and clinical characteristics.
DISCUSSION
The dismal prognosis of COVID-19 in patients with hematological
malignancies is well established [38]. There is emerging evidence,
suggesting reduced SARS-CoV-2 vaccine effectiveness in these
patients [18, 19, 28–30, 39, 20–27]. However, to our knowledge,
there is no data on the immune landscape of hematological
patients prior vaccination, nor if it can help decipher the
mechanism underlying the lack of response (particularly in
unexpected cases) and, ultimately, predict seroconversion. Here
we performed a comprehensive immunological characterization
of hematological patients prior to vaccination, which shows
marked differences when compared to HCP of similar age. These
analyses also exposed the extent of immunosuppression induced
by anticancer treatment and uncovered that immune dysregula-
tion is present before and persists after therapy. Our results
Fig. 6 Immune biomarkers of immunogenicity. A Odds ratio univariate analysis with 95% confidence intervals (CI) of variables included in
the logistic regression model. B Logistic regression coefficients with treatment-related features as well as immune biomarkers associated with
generation of ≥553.5 IU/mL of IgG antibodies against the receptor-binding domain (RBD) of the S-glycoprotein. C Area under the curve (AUC)
of prediction probabilities of patients’ dataset. D Correlation matrix of immune and treatment-related features. E Fourfold cross-validation of
AUC of prediction probabilities of patients’ dataset.
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translated into cutoffs for broad use of new immune biomarkers to
predict antibody response after vaccine for COVID-19 in hemato-
logical patients.
As expected, most of the significant differences in the immune
landscape of this cohort of patients were observed in the B-cell
compartment. More importantly, the marked reduction in the
frequency of numerous B-cell subsets observed in patients with
B-cell lymphoproliferative disorders, monoclonal gammopathies,
and to less extent, Hodgkin lymphoma, translated into lower anti-
RBD and anti-S immunoglobulin levels after second-dose SARS-
CoV-2 vaccination. Furthermore, due to the multiplex nature of the
serological flow cytometry assay used in this study, we unveiled
that hematological patients had reduced indexes of both IgG and
IgA antibodies. Although the roles of IgA and mucosal immunity in
COVID-19 protection remain unknown [40], IgA antibodies are
generally considered as the most important immunoglobulin to
neutralize infectious pathogens in the respiratory tract.
Seropositivity remains an imperfect proxy for clinically protec-
tive immunity against SARS-CoV-2 [41]. Here we reported rates of
seroconversion and IgG levels against the RBD fragment of the
Spike glycoprotein, which is the major target of neutralizing
antibodies. We established a cutoff of 553.5 IU/mL, because it was
the median value found in patients and it clearly segregated a few
HCP with antibody titers below the cutoff from the remaining
control group. Of note, only four HCP developed (mild) COVID-19
after vaccination, which reinforces that the levels of antibody
production above this concentration are clinically meaningful to
prevent symptomatic infection. Although it was outside the scope
of our study, the simultaneous analysis of seroconversion rates
and antibody concentration yielded interesting observations. First,
vaccination with mRNA-1273 yielded significantly higher anti-RBD
IgG titers in hematological patients than BNT162b2, as described
elsewhere [42]. Second, although patients with Hodgkin lym-
phoma may generally produce antibodies, their titers were lower
than those of HCP. Third, seroconversion rates between patients
with a mature B-cell and PC neoplasm were not considerably
different, but immunogenicity was significantly weaker in those
with monoclonal gammopathies. Fourth, although seroconversion
rates were similar between patients that never received anticancer
therapy and those that were off-treatment, antibody production
was impaired in the latter. Thus, ongoing and future analysis
should focus on antibody concentration beyond seroconversion
rates and use if possible, assays that are calibrated against the
WHO Standard for cross-study comparison.
Using anti-RBD and anti-S immunoglobulin assays as a
surrogate for COVID-19 immunity in lieu of neutralizing antibodies
against SARS-CoV-2 is controversial. However, it is reasonable to
consider that anti-RBD and anti-S titers would be highly correlated
with neutralizing antibody activity [15], and such a correlation was
recently shown in a cohort of hematological patients [39]. Another
limitation of this study is that antibody titers do not fully account
for protection against COVID-19 compared to other forms of
immunity such as SARS-CoV-2-specific memory T cells, which may
be protective even in seronegative patients. Noteworthy, a
reduced T-cell response compared to healthy individuals and
patients with solid cancer, has been detected in those with
hematological malignancies after SARS-CoV-2 vaccination [43, 44].
Although measuring T-cell specificity was outside the scope of this
study, we showed that, when compared to HCP of similar age, the
T-cell compartment was significantly altered in hematological
patients, particularly those with a monoclonal gammopathy, and
in those on or off-treatment. Interestingly, we observed in these
patients a pronounced reduction of Tfh cell types, which play an
essential role in regulating the germinal center reaction and,
consequently, the generation of high-affinity antibodies [45, 46].
Thus, our results may shed some light on the low rate of T-cell
responses in hematological patients [39, 44], particularly in
seronegative cases [44].
In MM, a positive correlation between serological response and
CD19+ or CD4+ lymphocyte counts was most recently observed,
while CD8+ T-cell counts were negatively correlated [47]. In
another study that included a more heterogeneous population of
patients with hematological malignancies, the strong correlation
between CD19+ B cells and serological response was confirmed,
and there was no correlation between antibody concentration and
CD4+ or CD8+ T cells [39]. Of note, CD19+ B-cell counts had
independent predictive value in the MM cohort and in the larger
series of patients with hematological malignancies [39, 47]. Here
we uncovered the presence of a distinct immunotype that,
although significantly associated with some disease and
treatment-related features, identified patients with a B-cell and a
PC neoplasm with more frequent seronegativity and lower
antibody titers after second-dose vaccination. More importantly,
our results show that CD4+, CD8+, and CD19+ lymphocytes, and
many of their respective subsets are essential for vaccine
effectiveness and should be monitored to predict immunogeni-
city. Increased numbers of neutrophils and classical monocytes
were significantly associated with poor antibody response, and
this could be related to their immunosuppressive phenotype [48].
The influence of anticancer treatment and timing of the
immune response to SARS-CoV-2 remains a topic of clinical
interest and controversy. Thus, and until more definitive data
emerges, decisions around delivery or interruption of anticancer
therapy should be based on individual risk-benefit assessment
incorporating factors including cancer prognosis and patient
comorbidities. Here we aimed to provide new biomarkers to help
on such decisions and thus, we identified six immune cell types
that depict patients’ immune landscape (i.e., percentages of
immunosuppressive cells and of T- and B-cell subsets representa-
tive of the cellular and humoral immunity) and are independent of
other disease features in order to predict immunogenicity prior to
vaccination. Despite the complex phenotype of some immune cell
types, which is the result of the holistic and computational flow
cytometry analysis we performed, there are standardized methods
for their quantification [49]. Immune profiling prior vaccination for
COVID-19 could be particularly informative in patients that are off
active treatment, who are expected to become seropositive but
may have poor antibody response due to tumor-related immune
dysregulation and may benefit from third-dose vaccination.
Interestingly, we found that hematological patients with
undocumented SARS-CoV-2 infection developed median antibody
titers after two doses that were similar to those found in HCP. Thus,
our data reproduces previous findings in non-cancer patients
[50, 51] and could suggest that a third challenge to SARS-CoV-2
antigens can improve immunogenicity. Just recently, the US Food
and Drugs Administration amended the emergency use authoriza-
tion for the BNT162b2 and mRNA-1273 COVID-19 vaccines to allow
for an additional dose for certain people with compromised
immune systems. That group includes, specifically, individuals over
65 years old, solid organ transplant recipients, or those who are
diagnosed with conditions that are considered to be equally
immunocompromised. Our study exposes the depth of immune
dysregulation in patients with hematological malignancies and
urges reflection on whether immune profiling before boosting is
warranted to identify optimal timing of third-dose vaccination.
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